Universidade Estadual de Montes Claros (UNIMONTES), 39401-089 Montes Claros, MG, Brazil.
Hum Immunol. 2013 Dec;74(12):1563-74. doi: 10.1016/j.humimm.2013.08.272. Epub 2013 Aug 28.
The study population comprised HNSCC patients, risk-positive controls (tabagism and alcoholism habits), and risk-negative controls (without risk factors). Significant increases in the activation status of CD4(+)and CD8(+) T-cells, and higher migration potentials of lymphocytes were observed in HNSCC patients compared with control groups. Although decreased frequency of CD19(+)-B lymphocytes was observed in HSNCC patients, a higher percentage of HLA-DR(+)CD19(+)-B lymphocytes was detected in these individuals as compared with other evaluated groups. Metastasis and tumor grading were the major pathological parameters associated with significant alterations in the expression of activation molecules on circulating CD4(+) and CD8(+) T-cells. A reduced frequency of CD38-expressing CD8(+) T-cells was the most relevant biomarker associated with HNSCC aggressiveness. Performance analysis suggested a cut-off point for the CD8(+)CD38(+)/CD8(+) T-cell ratio of 7.0 for segregating patients according to tumor grading. In contrast, a higher proportion of CD8(+)CD54(+)/CD8(+) T-cells could represent a relevant biomarker associated with metastasis in HNSCC patients, and performance analysis suggested a cut-off point for the CD8(+)CD54(+)/CD8(+) T-cell ratio of 30 for segregating patients according to absence or presence of metastasis. The results obtained can increment immunological aspects of HNSCC and provide tools for the determination of cut-off scores of clinically relevant immunophenotypic prognostic biomarkers.
研究人群包括头颈部鳞状细胞癌(HNSCC)患者、风险阳性对照组(吸烟和饮酒习惯)和风险阴性对照组(无风险因素)。与对照组相比,HNSCC 患者的 CD4(+)和 CD8(+)T 细胞激活状态显著增加,淋巴细胞迁移潜力更高。尽管 HSNCC 患者的 CD19(+)-B 淋巴细胞频率降低,但与其他评估组相比,这些个体中 HLA-DR(+)CD19(+)-B 淋巴细胞的比例更高。转移和肿瘤分级是与循环 CD4(+)和 CD8(+)T 细胞上激活分子表达的显著改变相关的主要病理参数。CD8(+)T 细胞表达 CD38 的频率降低是与 HNSCC 侵袭性最相关的生物标志物。性能分析表明,CD8(+)CD38(+)/CD8(+)T 细胞比值的截断点为 7.0,可根据肿瘤分级对患者进行分类。相比之下,CD8(+)CD54(+)/CD8(+)T 细胞的比例升高可能代表 HNSCC 患者转移相关的一个重要生物标志物,性能分析表明,CD8(+)CD54(+)/CD8(+)T 细胞比值的截断点为 30,可根据是否存在转移对患者进行分类。所得结果可以增加对头颈部鳞状细胞癌的免疫学认识,并提供用于确定临床相关免疫表型预后生物标志物的截断评分的工具。